Published in J Neurochem on July 01, 2001
Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A (2007) 3.03
Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology (2008) 1.32
Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip. EMBO J (2009) 1.16
Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. J Proteome Res (2008) 1.09
Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One (2010) 0.99
Microarrays in Parkinson's disease: a systematic approach. NeuroRx (2006) 0.96
Role and regulation of ferritin H in rotenone-mediated mitochondrial oxidative stress. Free Radic Biol Med (2008) 0.94
Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci (2014) 0.93
Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo. Neurobiol Dis (2008) 0.92
Exploiting microarrays to reveal differential gene expression in the nervous system. Genome Biol (2003) 0.90
Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson's disease. Neurochem Int (2007) 0.90
Whole genome expression analyses of single- and double-knock-out mice implicate partially overlapping functions of alpha- and gamma-synuclein. Neurogenetics (2007) 0.89
MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway. Br J Pharmacol (2015) 0.88
Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption. Transl Psychiatry (2011) 0.87
Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene. Brain Res (2008) 0.81
Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum. Neuroscience (2008) 0.80
Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. J Neural Transm (Vienna) (2006) 0.78
Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia. Brain Struct Funct (2014) 0.77
Signal oscillation is another reason for variability in microarray-based gene expression quantification. PLoS One (2013) 0.76
Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations and Loss of Dopamine Neurons in the Mouse Midbrain In Vivo. PLoS One (2017) 0.75
Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med (2001) 3.80
Induction of meiosis in Saccharomyces cerevisiae depends on conversion of the transcriptional represssor Ume6 to a positive regulator by its regulated association with the transcriptional activator Ime1. Mol Cell Biol (1996) 2.79
A phenylethylamine oxidising defect in migraine. Nature (1974) 2.28
Insulin production by human embryonic stem cells. Diabetes (2001) 2.20
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Conjugation defect in tyramine-sensitive migraine. Nature (1971) 1.91
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Multiple forms of rat brain monoamine oxidase. Nature (1969) 1.77
Properties of purified, soluble monoamine oxidase. Can J Biochem (1966) 1.76
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
Multiple forms of human brain mitochondrial monoamine oxidase. Nature (1970) 1.69
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Multiple forms of monoamine oxidase: functional significance. Pharmacol Rev (1972) 1.56
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Urological symptomatology in patients with reflex sympathetic dystrophy. J Urol (1996) 1.42
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem (2001) 1.30
Superior laryngeal nerve paresis and paralysis. J Voice (1996) 1.28
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
Which plasma antioxidants are most related to fruit and vegetable consumption? Am J Epidemiol (2001) 1.25
Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol (1998) 1.24
Heart rate and blood pressure changes with endurance training: the HERITAGE Family Study. Med Sci Sports Exerc (2001) 1.23
Effect of iron chelators on dopamine D2 receptors. J Neurochem (1985) 1.22
Wound zygomycosis (mucormycosis) in otherwise healthy adults. Am J Med (1988) 1.22
Promotion of 4-hydroxy-3-methoxyphenylglycol formation in man by reserpine. Nature (1968) 1.19
Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl (1997) 1.16
Alterations in body weight and composition consequent to 20 wk of endurance training: the HERITAGE Family Study. Am J Clin Nutr (1999) 1.16
Fas (CD95/Apo-1)-mediated damage to ventricular myocytes induced by cytotoxic T lymphocytes from perforin-deficient mice: a major role for inositol 1,4,5-trisphosphate. Circ Res (1998) 1.13
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (1991) 1.13
Ultrasound-guided fine-needle aspiration biopsy of the thyroid: role of on-site assessment and multiple cytologic preparations. Diagn Cytopathol (2000) 1.12
Endothelial cells from bovine adrenal medulla develop capillary-like growth patterns in culture. Proc Natl Acad Sci U S A (1985) 1.11
Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol (1995) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Leptin reverses the inhibitory effect of caloric restriction on longitudinal growth. Endocrinology (2003) 1.10
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol (1977) 1.10
Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature (1972) 1.09
Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem (2006) 1.08
The binding of (14C)phenethylhydrazine to rat liver monoamine oxidase. Biochem Pharmacol (1975) 1.08
Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem (1996) 1.07
The metabolism of 5-hydroxytryptamine and beta-phenylethylamine in perfused rat lung and in vitro. Br J Pharmacol (1979) 1.07
Physicochemical properties, development, and regulation of central and peripheral monoamine oxidase activity. Adv Biochem Psychopharmacol (1974) 1.07
Thyroid nodules with FNA cytology suspicious for follicular variant of papillary thyroid carcinoma: follow-up and management. Diagn Cytopathol (2000) 1.06
Expression of vascular antigens by bone cells during bone regeneration in a membranous bone distraction system. Histochem Cell Biol (2001) 1.06
Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta (2004) 1.06
On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm (1978) 1.05
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem (1991) 1.04
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem (1992) 1.04
Decreased monoamine oxidase activity in liver of iron-deficient rats. Can J Biochem (1969) 1.03
Heterogeneity of rat brain mitochondrial monoamine oxidase. Adv Biochem Psychopharmacol (1974) 1.00
Blood lipid response to 20 weeks of supervised exercise in a large biracial population: the HERITAGE Family Study. Metabolism (2000) 1.00
C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest (2000) 1.00
An interactive CD-ROM for nutrition screening and counseling. Am J Public Health (2000) 1.00
The oestrous cycle and monoamine oxidase activity. Br J Pharmacol (1973) 0.99
Genome-wide linkage scans for prediabetes phenotypes in response to 20 weeks of endurance exercise training in non-diabetic whites and blacks: the HERITAGE Family Study. Diabetologia (2005) 0.99
Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol (1981) 0.99
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem (1986) 0.98
Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med (1979) 0.98
Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem (1991) 0.98
Brain iron: a lesson from animal models. Am J Clin Nutr (1989) 0.98
Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab (1994) 0.98
The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa. Metabolism (1992) 0.97
Green tea polyphenol (-)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. J Neurochem (2005) 0.96
Nutritional iron and dopamine binding sites in the rat brain. Pharmacol Biochem Behav (1982) 0.96
Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol (1981) 0.96
Proceedings: Substrate and strain-dependent differences in the development of monoamine oxidase in the rat brain. Br J Pharmacol (1975) 0.96
Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta (1996) 0.95
The use of laparoscopy in abdominal emergencies. Surg Endosc (2003) 0.95
Metabolism of phenylethylamine in rat isolated perfused lung: evidence for monoamine oxidase 'type B' in lung. Br J Pharmacol (1976) 0.94
Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J Neurochem (1996) 0.93
Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann N Y Acad Sci (2000) 0.93
The effect of yohimbine on brain serotonin metabolism, motor behavior and body temperature of the rat. Eur J Pharmacol (1971) 0.93
Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem (1991) 0.93
Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem (1995) 0.92
5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats. Br J Pharmacol (1985) 0.92
The influence of tissue environment on the rates of metabolic processes and the properties of enzymes. Biochem Pharmacol (1975) 0.92
Impaired iron homeostasis in Parkinson's disease. J Neural Transm Suppl (2000) 0.91
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol (1987) 0.91
Growth hormone and insulin-like growth factor-I increase macrophage uptake and degradation of low density lipoprotein. Endocrinology (1992) 0.91
Pharmacology of selegiline. Neurology (1996) 0.90
Voice range in superior laryngeal nerve paresis and paralysis. J Voice (1998) 0.90
MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J Neurol (2000) 0.90
Cardiac output and stroke volume changes with endurance training: the HERITAGE Family Study. Med Sci Sports Exerc (2001) 0.89
Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm Suppl (1995) 0.89
Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol (1993) 0.89
Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats. Int J Dev Neurosci (1986) 0.89
Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol (1999) 0.89
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm (Vienna) (2001) 0.89
Effect of metabolic acidosis on the growth hormone/IGF-I endocrine axis in skeletal growth centers. Kidney Int (2000) 0.88